$5.30
0.75% today
Nasdaq, Nov 04, 10:00 pm CET
ISIN
NL0015436031
Symbol
CVAC

CureVac N.V. Stock price

$5.30
-0.11 2.03% 1M
+1.83 52.74% 6M
+1.89 55.43% YTD
+2.59 95.57% 1Y
-1.90 26.39% 3Y
-43.58 89.16% 5Y
-50.60 90.52% 10Y
-50.60 90.52% 20Y
Nasdaq, Closing price Tue, Nov 04 2025
-0.04 0.75%
ISIN
NL0015436031
Symbol
CVAC
Industry

New AI Insights on CureVac N.V. Insights AI Insights on CureVac N.V.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$788.0m
Net debt
positive
Cash
$456.0m
Shares outstanding
225.2m
Valuation (TTM | estimate)
P/E
5.4 | negative
P/S
2.0 | 17.2
EV/Sales
1.3 | 11.3
EV/FCF
3.5
P/B
1.8
Financial Health
Equity Ratio
86.8%
Return on Equity
23.3%
ROCE
33.5%
ROIC
79.5%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$588.2m | $69.7m
EBITDA
$262.5m | $-117.1m
EBIT
$239.8m | $-144.9m
Net Income
$223.1m | $-133.6m
Free Cash Flow
$226.0m
Growth (TTM | estimate)
Revenue
675.1% | -88.7%
EBITDA
184.9% | -151.6%
EBIT
171.8% | -170.8%
Net Income
169.5% | -171.5%
Free Cash Flow
159.4%
Margin (TTM | estimate)
Gross
94.8%
EBITDA
44.6% | -168.0%
EBIT
40.8%
Net
37.9% | -191.7%
Free Cash Flow
38.4%
More
EPS
$1.0
FCF per Share
$1.0
Short interest
0.8%
Employees
904
Rev per Employee
$680.0k
Show more

Is CureVac N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

CureVac N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a CureVac N.V. forecast:

6x Buy
46%
7x Hold
54%

Analyst Opinions

13 Analysts have issued a CureVac N.V. forecast:

Buy
46%
Hold
54%

Financial data from CureVac N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
588 588
675% 675%
100%
- Direct Costs 31 31
83% 83%
5%
558 558
613% 613%
95%
- Selling and Administrative Expenses 85 85
1% 1%
14%
- Research and Development Expense 181 181
47% 47%
31%
263 263
185% 185%
45%
- Depreciation and Amortization 23 23
9% 9%
4%
EBIT (Operating Income) EBIT 240 240
172% 172%
41%
Net Profit 223 223
170% 170%
38%

In millions USD.

Don't miss a Thing! We will send you all news about CureVac N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CureVac N.V. Stock News

AD HOC NEWS
14 days ago
Bei der geplanten Übernahme des Tübinger Impfstoff-Entwicklers Curevac NL0015436031 durch den Mainzer Konkurrenten Biontech US09075V1026 folgt der nächste Schritt.
Positive
Seeking Alpha
about one month ago
CureVac is a pioneering biotech company focused on mRNA drugs for oncology and vaccines. In biotech, value derives from research quality, patent strength, and clinical success probability, not current revenues. CVAC boasts over 25 years of research and nearly 1,000 mRNA patents, highlighting its intellectual property strength.
Neutral
Accesswire
3 months ago
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all shares of CureVac, uniting two highly complementary German companies to bring transformative mRNA-based treatments to patients globally Entered into agreements to resolve and dismiss all pen...
More CureVac N.V. News

Company Profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Employees 904
Founded 2020
Website www.curevac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today